| |
Boehringer Ingelheim HCV R&D Mono and HIV Coinfection: Faldaprevir, Non-nuc Deleobuvir (BI127) - Mono- and HCV/HIV Coinfection, NS5A PPI-668
|
| |
| |
Prevalence, Treatment, and Comorbidities of Hepatitis C Infection (HCV) Among Patients With Commercial and Medicaid Insurance - (05/21/13)
Clinical Pharmacology Presented at 14th Clin Pharm Workshop at EASL 2013 - Boehringer Ingelheim J. Kort Pres. (LINK)
Study Results For PPI668 NS5A, BI335 protease, BI127 non-nuc polymerase - new collaboration between Presidio & Boerhinger Ingelheim
http://www.natap.org/2013/HCV/031513_01.htm
Presidio Pharmaceuticals Announces Collaboration with Boehringer Ingelheim The Parties to Initiate a Phase IIa Trial of an All-Oral Combination of Presidio's HCV NS5A inhibitor (PPI-668) with Faldaprevir (BI201335) and BI207127 for the Treatment of Patients with Hepatitis C
BI 201335, a potent HCV NS3 protease inhibitor, in treatment-naïve and -experienced chronic HCV genotype-1 infection: genotypic and phenotypic analysis of the NS3 protease domain, EASL 2009
http://www.natap.org/2009/EASL/EASL_88.htm
Safety and antiviral activity of BI 201335, a new HCV NS3 protease inhibitor, in treatment-naïve patients with chronic hepatitis C genotype 1 infection given as monotherapy and in combination with peginterferon alfa-2a (P) and ribavirin ®
http://www.natap.org/2008/AASLD/AASLD_13.htm
Safety and antiviral activity of BI 201335, a new HCV NS3 protease inhibitor, in combination therapy with peginterferon alfa-2a (P) and ribavirin (R) for 28 days in P+R treatment-experienced patients with chronic hepatitis C genotype 1 infection (2)
http://www.natap.org/2008/AASLD/AASLD_32.htm
BI 207127 is a potent HCV RNA polymerase inhibitor during 5 days monotherapy in patients with chronic hepatitis C http://www.natap.org/2009/AASLD/AASLD_10.htm
PPI-668, A Potent New Pan-Genotypic HCV NS5A Inhibitor: Phase 1 Efficacy and Safety http://www.natap.org/2012/AASLD/AASLD_34.htm
CROI: Pharmacokinetic interactions of darunavir/ritonavir, efavirenz, and tenofovir with the HCV protease inhibitor faldaprevir in healthy volunteers - (03/04/13)
CROI: STARTVerso 4: High rates of early virologic response in HCV genotype 1/HIV-co-infected patients treated with faldaprevir plus pegIFN and RBV - (03/04/13)
An Analysis of Response Rates by Fibrosis Stage in Patients Treated With Faldaprevir, BI 207127, and Ribavirin in the SOUND-C2 Study - (05/20/13)
|
|
| |
| |
|
|
|
